Pepti · Catalog · ACE-031

Myostatin / ActRIIB pathway · research-use

ACE-031 (ramatercept) OEM supply.

Lyophilized recombinant ActRIIB-Fc fusion protein, supplied research-use only in 1 mg vials with per-lot HPLC/MS COA and full OEM documentation.

ACE-031 lyophilized vial
ACE-031HPLC ≥ 98%MS confirmed1mg

Vial illustrations reflect supplied lyophilized format. Distribution scope and destination market confirmed before invoicing.

CompoundACE-031
CAS number1169766-01-1
ClassGrowth-hormone axis & repair
Molecular weight≈77.24 kDa (calculated ActRIIB-Fc homodimer; glycosylated native runs ~90–100 kDa apparent)
FormLyophilized powder, sterile glass vial
Purity target≥ 98% by HPLC
Vial formats1mg
DocumentationCOA + HPLC + MS, batch lot file where available
Distribution scopeResearch use, worldwide
StorageStore lyophilized ACE-031 at -20°C, protected from light and moisture. After reconstitution, keep at 2-8°C for near-term research use or aliquot and freeze at -20°C to -80°C to minimize freeze-thaw cycles. Follow lot-specific handling stated on the COA.

MOQ & lead time

TierQuantityLead time
Sample lotFrom 50 vials3–7 days
Production lot200–1,000 vials10–14 days
OEM repeat1,000+ vials14–18 days, scheduled

ACE-031 (ramatercept) is a recombinant soluble activin receptor type IIB (ActRIIB)–IgG1 Fc fusion protein that acts as a myostatin/activin ligand trap, supplied by Pepti as research-use material in 1 mg vials.

Documentation

Batch documentation support for ACE-031 lots.

COA / HPLC / MS document support where available. Distribution scope confirmed before invoicing.

HPLC purity

Reverse-phase HPLC with UV detection; purity target reported per lot with related-substance reporting on request.

MS identity

Mass spectrometry identity confirmation against the ACE-031 reference profile.

Lot traceability

Compound prefix and lot serial printed on the vial label and repeated in the document pack and carton.

FAQ

ACE-031 — frequently asked by B2B buyers.

Is ACE-031 a peptide or a recombinant protein?

ACE-031 (ramatercept) is a recombinant Fc-fusion protein of roughly 77 kDa (a glycosylated ActRIIB-Fc homodimer), not a short synthetic peptide. It is produced in a mammalian expression system and handled as a biologic; lot-specific identity and mass are documented on the COA.

What documentation ships with each lot?

Each lot is supplied with a Certificate of Analysis covering identity (mass spec), purity (HPLC and SDS-PAGE), and standard protein-release checks. Endotoxin, appearance, and reconstitution notes can be added on request, and analytical traces are available under RFQ/NDA for OEM buyers.

What are the vial size and MOQ, and do you support private-label/OEM orders?

Catalog format is 1 mg per vial with a minimum order of 50 vials. Bulk quantities, custom fill volumes, and private-label/OEM packaging (custom vials, labels, and kit configurations) are available on request with volume-based pricing.

Is ACE-031 approved for human or clinical use?

No. ACE-031 is offered strictly for laboratory research use. Clinical development of ramatercept was discontinued, and the material is not intended for human, veterinary, therapeutic, or diagnostic use. Buyers are responsible for compliance with their local regulations.

Can you confirm the CAS and specifications before we order?

Yes. The compound resolves to ramatercept, CAS 1169766-01-1, with a reported molecular weight near 77 kDa for the ActRIIB-Fc construct. We provide the current spec sheet and a representative COA on request so your team can verify identity and purity before purchase.

WhatsApp us